Top Health Tech Companies in Melbourne (61)
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is described as sizable and growing rapidly, with independent reporting and credit analyses pointing to continued double‑digit expansion. ARR and ACV are characterized as increasing consistently since 2022.
Customer Loyalty & Retention: Retention is depicted as very high, with consistent expansion within existing accounts that supports sustained recurring revenue growth. Commentary highlights strong share‑of‑wallet gains and durable renewals across healthcare customers.
Product Line Growth: The portfolio has broadened through repeated acquisitions (e.g., SecureLink, Verosint) and new capabilities such as passwordless authentication and agentic identity management. These moves signal active investment to expand addressable use cases and deepen the platform.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.
Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.
Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.
Teladoc Health is on a mission to empower all people everywhere to live healthier lives by transforming the healthcare experience. Recognized as the world leader in whole-person virtual care, Teladoc Health addresses the full spectrum of health and well-being — powered by human expertise, advanced technology and insights—to deliver improved clinical outcomes at scale. Serving more than 175 countries and...
Teladoc Health's Top Stability & Growth Strengths
Strong Market Position & Advantage: Scale across enterprise and direct‑to‑consumer channels (including 17.1 million visits in 2025) and a broad integrated‑care stack position the company as a top multi‑specialty virtual‑care operator. External signals such as BetterHelp’s category scale and a top‑tier satisfaction ranking support durable competitive standing.
Cost & Operational Efficiency: Operating performance shows improving efficiency with a materially narrower net loss and stable adjusted EBITDA despite revenue pressure. Margin expansion in Integrated Care indicates better unit economics at scale.
Market Expansion: International revenue grew while insurance acceptance for BetterHelp expanded and new channels were pursued, signaling ongoing market expansion. These moves diversify geography and payer mix beyond U.S. cash‑pay exposures.
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 38 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New...
Bupa's Top Stability & Growth Strengths
Strong Revenue Growth: Group results show double‑digit revenue and underlying profit growth in 2024, with customers rising sharply. 2025 materials indicate continued revenue and profit increases alongside a larger customer base, with growth remaining solid even excluding first‑time consolidation effects.
Strong Market Position & Advantage: Independent market analysis places Bupa as the UK PMI leader within a concentrated 'big four', and official statistics show it as the largest fund in Australian private health insurance. Bupa Global is viewed as a tier‑one IPMI provider, and the insurer‑plus‑provider model strengthens competitive positioning across multiple regions.
Market Expansion: Company updates highlight ongoing expansion of clinics, dental centres, hospitals and digital health (Blua), with dozens of new sites opened in 2024 and further additions in 2025. Portfolio moves such as consolidating Niva Bupa in India and adding UK provision assets broaden reach into fast‑growing markets and channels.
Lyrebird Health is an AI medical scribe that securely listens in the background throughout your consultation, then intelligently generates a note tailored to your style, ready to transfer into the medical record. We're on a mission to automate all non-patient-facing work so that doctors can spend more time with patients and less time on paperwork.
Welcome to Cabrini Health Cabrini is owned and operated by the Missionary Sisters of the Sacred Heart of Jesus who came to Australia in 1948 to take over the management of a 45-bed community hospital named St Benedict’s. Cabrini now has more than 800 beds and a comprehensive range of health services. There are acute facilities at Malvern and Brighton. The...
Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.
Medtronic is a global healthcare solutions company operating in approximately 160 countries. We are committed to improving lives through our medical technologies, services, and solutions. Since our beginning, 60 years ago, our Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. The Mission is our ethical framework and inspirational goal guiding...
Medtronic's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue accelerated to the fastest annual pace in a decade in FY2026, with momentum evident into the fourth quarter. Management’s outlook points to continued upper single‑digit organic expansion in the coming year.
Healthy Cash Flow: Strong free cash flow and a long-running pattern of dividend increases indicate durable cash generation. Recent dividend actions and ongoing cash returns underscore capacity to fund investment and tuck‑in M&A.
Strong Market Position & Advantage: Scale leadership at the top of global medtech by revenue, with breadth across Cardiovascular, Neuroscience, and Medical Surgical, supports resilience. Category strength in areas like cardiac pacing and ablation provides commercial leverage for new launches.
The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced...
The Walter and Eliza Hall Institute of Medical Research (WEHI) is a medical research institute dedicated to improving health outcomes through discovery, translation, and education. WEHI focuses on developing treatments for cancer, immune disorders, infections, and diseases of development and ageing, collaborating to make life-changing scientific discoveries that help people live healthier, longer lives.
InstantScripts Pty Ltd is an Australian-owned telehealth service and online medical clinic, wholly owned by Wesfarmers Health. Through its website and app, it connects Australians with registered doctors for consultations, prescriptions, medical certificates, pathology and specialist referrals, plus selected treatment and ongoing-care services. Operating 24/7, the company aims to make professional healthcare more accessible, convenient and flexible across Australia from...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
The International SOS Group of Companies is in the business of saving lives, protecting global workforces from health and security threats. We deliver customised health, security risk management and wellbeing solutions to fuel our clients’ growth and productivity. In the event of extreme weather, an epidemic or a security incident, we provide an immediate response providing peace of mind. Our...
RSL LifeCare is an Australian social purpose organisation serving veterans, seniors and their families. It provides aged care through residential homes and personal home care, retirement living in villages, and veteran support services. Its integrated wellbeing and care approach operates across more than 60 sites in New South Wales and the Australian Capital Territory, with the stated purpose of enriching...
Liven is a product company that develops a global ecosystem of tools designed to help people gain self-observability and improve their mental well-being. Their primary offering is a self-discovery companion app featuring AI coaching, mood trackers, and well-being tests, alongside certified online coaching and supplements, all aimed at helping users build a deeper relationship with themselves.
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
Sagility is a technology-led healthcare operations and business process optimization partner serving payers and providers. It combines healthcare expertise with artificial intelligence, intelligent automation, analytics, cloud platforms, consulting, and BPaaS to streamline claims, membership, clinical, payment-integrity, provider-network, and revenue-cycle workflows across the healthcare ecosystem. Its goal is to reduce administrative costs, improve member and provider experiences, and support better clinical...
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with...
Stryker's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double-digit annual sales expansion through 2025, with management guiding to continued organic growth into 2026.
Strong Market Position & Advantage: Evidence highlights leadership in orthopedic robotics and top-tier standings among global medtech peers, with notable share in joint replacement and integrated OR technologies.
Diversified Revenue Streams: Multiple segments and recent vascular-focused acquisitions broaden growth drivers and reduce reliance on any single category.
